Waters stock surges 3% as strong pharma demand drives Q2 earnings beat

Published 04/08/2025, 11:44
 Waters stock surges 3% as strong pharma demand drives Q2 earnings beat

MILFORD, Mass. - On Monday, Waters Corporation (NYSE:WAT) reported second-quarter results that exceeded expectations, driven by robust instrument replacement trends among pharmaceutical customers and strong recurring revenue growth.

The analytical instruments maker’s shares jumped 2.99% in pre-market trading after the earnings release.

The company reported second-quarter adjusted earnings of $2.95 per share, slightly above analyst estimates of $2.94, while revenue climbed 9% to $771 million, significantly outpacing the consensus forecast of $748.04 million. On a constant currency basis, sales grew 8% YoY.

Waters saw particular strength in its pharmaceutical segment, which grew 11% in constant currency, while industrial sales increased 6%. The company’s recurring revenue, which includes service and chemistry products, rose 11% in constant currency, with chemistry revenue jumping 16%.

"Our team continues to execute extremely well and we delivered excellent results again this quarter, driven by robust instrument replacement trends–particularly among large pharma and CDMO customers," said Dr. Udit Batra, President & CEO of Waters Corporation.

The strong performance led Waters to raise its full-year 2025 outlook, now expecting constant currency sales growth of 5.5% to 7.5%, up from previous guidance. The company also increased its full-year adjusted EPS forecast to $12.95-$13.05, compared to the consensus estimate of $12.96.

For the third quarter, Waters projects constant currency sales growth of 5.0% to 7.0% and adjusted EPS between $3.15 and $3.25.

The company’s performance reflects continued momentum in its core business as it prepares for its upcoming combination with BD’s Biosciences & Diagnostic Solutions business, which Waters expects will accelerate its growth strategy into high-growth adjacent markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.